The development of novel immunotherapeutic approaches in multiple myeloma

References

• Harrison S J, Cook S J, Nibbs G, Prince H M. Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Rev Anticancer Ther 2006; 6: 1769–1785
   PubMed Web of Science ®Google Scholar
• Bollard C M, et al. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 2003; 110: 139–148
   PubMed Web of Science ®Google Scholar
• Dudley M E, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–2357
   PubMed Web of Science ®Google Scholar
• Small E J, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089–3094
   PubMed Web of Science ®Google Scholar
• Gratwohl A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092
   PubMed Web of Science ®Google Scholar
• van Rhee F. et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055–1061
   PubMed Web of Science ®Google Scholar
• Hsu F J, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 1997; 89: 3129–3135
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania F, Zhan S M, Gupta F, Pomtree S K, Lin M, et al. NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 2004-09-3707
   Web of Science ®Google Scholar
• Barratt-Boyes S M. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 1996; 43: 142–151
   PubMed Web of Science ®Google Scholar
• Timmerman J M, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526
   PubMed Web of Science ®Google Scholar
• Azuma T, et al. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2004; 10: 7402–7412
   PubMed Web of Science ®Google Scholar
• Frank C, Hundemer M, Ho A D, Goldschmidt H, Witzens-Harig M. Cellular immune responses against the cancer testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma 2008; 49: 7787–7784
   Web of Science ®Google Scholar
• Morgan R A, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126–129
   PubMed Web of Science ®Google Scholar
• Park J R, Digiusto D L, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15: 825–833
   PubMed Web of Science ®Google Scholar
• Klebanoff C A, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26: 111–117
   PubMed Web of Science ®Google Scholar
• Schumacher T NM, et al. Peptide selection by MHC class I molecules. 1991; 350: 703–706
   Google Scholar
• Haynes N M, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002; 100: 3155–3163
   PubMed Web of Science ®Google Scholar
• Westwood J A, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 2005; 102: 19051–19056
   PubMed Web of Science ®Google Scholar
• Hönemann D, Guru P, Westwood J A, Kershaw M H, Smyth M J, Trapani J A, et al. Targeting Lewis Y positive Multiple Myeloma with gene-modified T cells. 2007, International Society of Cellular Therapy Annual Meeting, Sydney
   Google Scholar
• Ritchie D S. Plasma cell lysate as an antigen source in multiple myeloma immunotherapy. Leuk Lymphoma 2007; 48: 1894–1895
   PubMed Web of Science ®Google Scholar
• Elrick L J, et al. Punish the parent not the progeny. Blood 2005; 105: 1862–1866
   PubMed Web of Science ®Google Scholar
• Matsui W, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332–2336
   PubMed Web of Science ®Google Scholar
• Matsui W, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190–197
   PubMed Web of Science ®Google Scholar